Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Willis JC"" wg kryterium: Autor


Wyświetlanie 1-8 z 8
Tytuł:
A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia.
Autorzy:
Panayiotidis P; Laikon General Hospital and National and Kapodistrian University of Athens, Athens, Greece.
Tumyan G; N.N. Blokhin Russian Cancer Research Centre, Moscow, Russian Federation.
Thieblemont C; AP-HP, Hôpital Saint-Louis, and Université de Paris, Paris, France.
Ptushkin VV; City Clinical Hospital Named After S.P. Botkin, Moscow, Russian Federation.
Marin-Niebla A; Hospital Universitari Vall d'Hebron, Barcelona, Spain.
García-Sanz R; Hospital Universitario de Salamanca (HUSA/IBSAL/CIBERONC), Salamanca, Spain.
Le Gouill S; Service d'Hématologie Clinique du CHU de Nantes, INSERM CRCINA Nantes-Angers, NeXT Université de Nantes, Nantes, France.
Stathis A; Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland, and Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.
Bottos A; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Hamidi H; Genentech, Inc, South San Francisco, CA, USA.
Katz P; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Perretti T; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Willis JC; Roche Products Ltd, Welwyn Garden City, UK.
Buske C; CCC Ulm, Institute of Experimental Cancer Research, University Hospital Ulm, Ulm, Germany.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2022 May; Vol. 63 (5), pp. 1058-1069. Date of Electronic Publication: 2022 Jan 19.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Lymphoma, B-Cell, Marginal Zone*/drug therapy
Waldenstrom Macroglobulinemia*/drug therapy
Adult ; Antibodies, Monoclonal, Humanized ; Humans ; Rituximab/therapeutic use
Czasopismo naukowe
Tytuł:
Outcomes following kidney transplantation in patients with sickle cell disease: The impact of automated exchange blood transfusion.
Autorzy:
Willis JC; Renal Medicine, King's College Hospital NHS Foundation Trust, London, United Kingdom.
Awogbade M; Haematological Medicine, King's College Hospital NHS Foundation Trust, London, United Kingdom.
Howard J; Haematology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Breen C; Nephrology and Transplantation, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Abbas A; Nephrology and Transplantation, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
Harber M; Renal Medicine, Royal Free London NHS Foundation Trust, London, United Kingdom.
Shendi AM; Renal Medicine, Royal Free London NHS Foundation Trust, London, United Kingdom.; Renal Medicine, Zagazig University, Zagazig, Egypt.
Andrews PA; Renal Medicine, Epsom and St Helier University Hospitals NHS Trust, London, United Kingdom.
Galliford J; Nephrology, Imperial College Healthcare NHS Trust, London, United Kingdom.
Thuraisingham R; Department of Renal Medicine and Transplantation, Barts Health NHS Trust, London, United Kingdom.
Gage A; Department of Renal Medicine and Transplantation, Barts Health NHS Trust, London, United Kingdom.
Shah S; Renal Medicine, King's College Hospital NHS Foundation Trust, London, United Kingdom.
Sharpe CC; Renal Medicine, King's College Hospital NHS Foundation Trust, London, United Kingdom.; Department of Inflammation Biology, King's College London, London, United Kingdom.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2020 Aug 13; Vol. 15 (8), pp. e0236998. Date of Electronic Publication: 2020 Aug 13 (Print Publication: 2020).
Typ publikacji:
Journal Article; Multicenter Study
MeSH Terms:
Exchange Transfusion, Whole Blood*
Kidney Transplantation*
Anemia, Sickle Cell/*complications
Anemia, Sickle Cell/*surgery
Kidney Failure, Chronic/*etiology
Kidney Failure, Chronic/*surgery
Adult ; Anemia, Sickle Cell/therapy ; Combined Modality Therapy ; Female ; Graft Survival ; Humans ; Kaplan-Meier Estimate ; Kidney Failure, Chronic/therapy ; London ; Male ; Middle Aged ; Retrospective Studies ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł:
Immune biomarkers: the promises and pitfalls of personalized medicine.
Autorzy:
Willis JC; Department of Experimental Immunobiology, Medical Research Council Centre for Transplantation, King's College London, SE1 9RT, UK, and at the National Institute for Health Research Biomedical Research Centre at Guy's and St Thomas' Hospital, London SE1 9RT, UK.
Lord GM; Department of Experimental Immunobiology, Medical Research Council Centre for Transplantation, King's College London, SE1 9RT, UK, and at the National Institute for Health Research Biomedical Research Centre at Guy's and St Thomas' Hospital, London SE1 9RT, UK.
Pokaż więcej
Źródło:
Nature reviews. Immunology [Nat Rev Immunol] 2015 May; Vol. 15 (5), pp. 323-9. Date of Electronic Publication: 2015 Mar 27.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms:
Biomarkers/*metabolism
Immune System Diseases/*metabolism
Precision Medicine/*methods
Humans ; Precision Medicine/economics
Czasopismo naukowe
    Wyświetlanie 1-8 z 8

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies